Login to Your Account



Financings Roundup

Aegerion Adds $50M Ahead of Lomitapide NDA in HoFH

By Jennifer Boggs


Monday, June 27, 2011
On a call with investors earlier this month, Aegerion Pharmaceuticals Inc.'s CEO, Marc Beer, said the firm was "in filing mode now," with plans to submit a new drug application for lomitapide in homozygous familial hypercholesterolemia (HoFH) by the end of this year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription